vs
BioRestorative Therapies, Inc.（BRTX）与Progyny, Inc.（PGNY）财务数据对比。点击上方公司名可切换其他公司
Progyny, Inc.的季度营收约是BioRestorative Therapies, Inc.的16245.1倍（$318.4M vs $19.6K）。Progyny, Inc.净利率更高（3.9% vs -16365.5%，领先16369.4%）。Progyny, Inc.同比增速更快（6.7% vs -54.7%）。Progyny, Inc.自由现金流更多（$48.6M vs $-2.5M）。过去两年Progyny, Inc.的营收复合增速更高（7.0% vs -25.2%）
BioRestorative Therapies, Inc.是一家临床阶段生物技术企业，专注于创新再生医学疗法的研发，核心管线覆盖慢性腰痛、代谢类疾病等未被满足的医疗需求领域，主要面向北美市场，推进细胞类创新候选治疗产品的临床开发工作。
Progyny, Inc.是总部位于美国的领先生育与家庭构建福利服务商，主要与企业雇主合作，提供试管婴儿、生育力保存、收养协助、代孕支持等综合生育相关福利方案，覆盖多个行业的雇员群体。
BRTX vs PGNY — 直观对比
营收规模更大
PGNY
是对方的16245.1倍
$19.6K
营收增速更快
PGNY
高出61.4%
-54.7%
净利率更高
PGNY
高出16369.4%
-16365.5%
自由现金流更多
PGNY
多$51.1M
$-2.5M
两年增速更快
PGNY
近两年复合增速
-25.2%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6K | $318.4M |
| 净利润 | $-3.2M | $12.5M |
| 毛利率 | 91.7% | 24.1% |
| 营业利润率 | -19516.8% | 4.8% |
| 净利率 | -16365.5% | 3.9% |
| 营收同比 | -54.7% | 6.7% |
| 净利润同比 | -96.0% | 18.5% |
| 每股收益（稀释后） | $-0.31 | $0.14 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BRTXPGNY
| Q4 25 | $19.6K | $318.4M | ||
| Q3 25 | $11.8K | $313.3M | ||
| Q2 25 | $303.3K | $332.9M | ||
| Q1 25 | $25.0K | $324.0M | ||
| Q4 24 | $43.3K | $298.4M | ||
| Q3 24 | $233.6K | $286.6M | ||
| Q2 24 | $89.1K | $304.1M | ||
| Q1 24 | $35.0K | $278.1M |
净利润BRTXPGNY
| Q4 25 | $-3.2M | $12.5M | ||
| Q3 25 | $-3.0M | $13.9M | ||
| Q2 25 | $-2.7M | $17.1M | ||
| Q1 25 | $-5.3M | $15.1M | ||
| Q4 24 | $-1.6M | $10.5M | ||
| Q3 24 | $-1.1M | $10.4M | ||
| Q2 24 | $-4.0M | $16.5M | ||
| Q1 24 | $-2.2M | $16.9M |
毛利率BRTXPGNY
| Q4 25 | 91.7% | 24.1% | ||
| Q3 25 | 10.4% | 23.2% | ||
| Q2 25 | 97.1% | 23.7% | ||
| Q1 25 | 88.4% | 23.4% | ||
| Q4 24 | 92.3% | 21.3% | ||
| Q3 24 | 92.2% | 20.7% | ||
| Q2 24 | 92.7% | 22.5% | ||
| Q1 24 | 100.0% | 22.4% |
营业利润率BRTXPGNY
| Q4 25 | -19516.8% | 4.8% | ||
| Q3 25 | -31432.3% | 6.9% | ||
| Q2 25 | -1089.8% | 7.3% | ||
| Q1 25 | -19230.1% | 7.5% | ||
| Q4 24 | -6212.8% | 5.3% | ||
| Q3 24 | -979.0% | 4.3% | ||
| Q2 24 | -2770.8% | 6.8% | ||
| Q1 24 | -11740.7% | 6.7% |
净利率BRTXPGNY
| Q4 25 | -16365.5% | 3.9% | ||
| Q3 25 | -25748.1% | 4.4% | ||
| Q2 25 | -875.8% | 5.1% | ||
| Q1 25 | -21359.2% | 4.6% | ||
| Q4 24 | -3778.6% | 3.5% | ||
| Q3 24 | -467.2% | 3.6% | ||
| Q2 24 | -4521.4% | 5.4% | ||
| Q1 24 | -6352.2% | 6.1% |
每股收益（稀释后）BRTXPGNY
| Q4 25 | $-0.31 | $0.14 | ||
| Q3 25 | $-0.33 | $0.15 | ||
| Q2 25 | $-0.30 | $0.19 | ||
| Q1 25 | $-0.64 | $0.17 | ||
| Q4 24 | $-0.20 | $0.12 | ||
| Q3 24 | $-0.13 | $0.11 | ||
| Q2 24 | $-0.50 | $0.17 | ||
| Q1 24 | $-0.33 | $0.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.0M | $112.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $356.7K | $516.0M |
| 总资产 | $4.1M | $742.4M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BRTXPGNY
| Q4 25 | $3.0M | $112.2M | ||
| Q3 25 | $4.5M | $134.0M | ||
| Q2 25 | $7.4M | $132.5M | ||
| Q1 25 | $9.1M | $109.2M | ||
| Q4 24 | $10.7M | $162.3M | ||
| Q3 24 | $13.1M | $91.5M | ||
| Q2 24 | $14.7M | $95.0M | ||
| Q1 24 | $16.4M | $115.0M |
股东权益BRTXPGNY
| Q4 25 | $356.7K | $516.0M | ||
| Q3 25 | $2.2M | $560.0M | ||
| Q2 25 | $4.8M | $515.0M | ||
| Q1 25 | $6.1M | $467.2M | ||
| Q4 24 | $8.5M | $422.1M | ||
| Q3 24 | $10.0M | $434.9M | ||
| Q2 24 | $10.8M | $456.2M | ||
| Q1 24 | $14.5M | $571.6M |
总资产BRTXPGNY
| Q4 25 | $4.1M | $742.4M | ||
| Q3 25 | $5.6M | $795.2M | ||
| Q2 25 | $8.5M | $761.0M | ||
| Q1 25 | $10.3M | $730.3M | ||
| Q4 24 | $12.3M | $607.1M | ||
| Q3 24 | $14.6M | $660.0M | ||
| Q2 24 | $16.1M | $698.6M | ||
| Q1 24 | $18.0M | $794.3M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.4M | $54.2M |
| 自由现金流经营现金流 - 资本支出 | $-2.5M | $48.6M |
| 自由现金流率自由现金流/营收 | -12728.8% | 15.3% |
| 资本支出强度资本支出/营收 | 406.5% | 1.8% |
| 现金转化率经营现金流/净利润 | — | 4.34× |
| 过去12个月自由现金流最近4个季度 | — | $191.8M |
8季度趋势，按日历期对齐
经营现金流BRTXPGNY
| Q4 25 | $-2.4M | $54.2M | ||
| Q3 25 | $-2.9M | $50.7M | ||
| Q2 25 | $-2.7M | $55.5M | ||
| Q1 25 | $-2.8M | $49.8M | ||
| Q4 24 | $-2.3M | $52.2M | ||
| Q3 24 | $-1.7M | $44.5M | ||
| Q2 24 | $-1.9M | $56.7M | ||
| Q1 24 | $-2.3M | $25.7M |
自由现金流BRTXPGNY
| Q4 25 | $-2.5M | $48.6M | ||
| Q3 25 | — | $46.0M | ||
| Q2 25 | — | $50.2M | ||
| Q1 25 | $-2.8M | $47.0M | ||
| Q4 24 | — | $50.3M | ||
| Q3 24 | $-1.8M | $42.7M | ||
| Q2 24 | — | $55.8M | ||
| Q1 24 | — | $24.9M |
自由现金流率BRTXPGNY
| Q4 25 | -12728.8% | 15.3% | ||
| Q3 25 | — | 14.7% | ||
| Q2 25 | — | 15.1% | ||
| Q1 25 | -11260.7% | 14.5% | ||
| Q4 24 | — | 16.8% | ||
| Q3 24 | -752.6% | 14.9% | ||
| Q2 24 | — | 18.4% | ||
| Q1 24 | — | 8.9% |
资本支出强度BRTXPGNY
| Q4 25 | 406.5% | 1.8% | ||
| Q3 25 | 0.0% | 1.5% | ||
| Q2 25 | 0.0% | 1.6% | ||
| Q1 25 | 145.6% | 0.9% | ||
| Q4 24 | — | 0.6% | ||
| Q3 24 | 25.0% | 0.6% | ||
| Q2 24 | — | 0.3% | ||
| Q1 24 | — | 0.3% |
现金转化率BRTXPGNY
| Q4 25 | — | 4.34× | ||
| Q3 25 | — | 3.65× | ||
| Q2 25 | — | 3.24× | ||
| Q1 25 | — | 3.31× | ||
| Q4 24 | — | 4.95× | ||
| Q3 24 | — | 4.27× | ||
| Q2 24 | — | 3.44× | ||
| Q1 24 | — | 1.52× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BRTX
暂无分部数据
PGNY
| Fertility Benefit Services | $208.6M | 66% |
| Pharmacy Benefit Services | $109.8M | 34% |
